Receptors for dopamine and somatostatin: Formation of hetero-oligomers with enhanced functional activity

Science

Volumn 288, Issue 5463, 2000, Pages 154-157

  Rocheville, Magalie ^a   Lange, Daniela C ^b   Kumar, Ujendra ^a   Patel, Shutish C ^c   Patel, Ramesh C ^b   Patel, Yogesh C ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b CLARKSON UNIVERSITY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; SOMATOSTATIN RECEPTOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; DOPAMINE RELEASE; MOLECULAR INTERACTION; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN INTERACTION; PROTEIN LOCALIZATION; RAT; RECEPTOR DENSITY; SOMATOSTATIN RELEASE;

ANIMALS; CELL MEMBRANE; CEREBRAL CORTEX; CHO CELLS; CORPUS STRIATUM; CRICETINAE; CYCLIC AMP; DIMERIZATION; FORSKOLIN; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HETEROTRIMERIC GTP-BINDING PROTEINS; HUMANS; LIGANDS; MALE; NEURONS; PYRAMIDAL CELLS; QUINPIROLE; RATS; RECEPTOR CROSS-TALK; RECEPTORS, DOPAMINE D2; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; SPIPERONE; SULPIRIDE; TRANSFECTION;

ANIMALIA;

EID: 0034616021     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.288.5463.154     Document Type: Article

References (35)

1. Y. C. Patel, in The Role of Somatostatin, vol. 4 of Basic and Clinical Aspects of Neuroscience Series, E. E. Muller, M. O Thorner, C. Weil, Eds. (Springer-Verlag, Berlin, 1992), pp. 1-16; J. Epelbaum, Prog. Neurobiol. 27, 63 (1986).
2. Y. C. Patel, in The Role of Somatostatin, vol. 4 of Basic and Clinical Aspects of Neuroscience Series, E. E. Muller, M. O Thorner, C. Weil, Eds. (Springer-Verlag, Berlin, 1992), pp. 1-16; J. Epelbaum, Prog. Neurobiol. 27, 63 (1986).
3. Y. C. Patel, Frontiers Neuroendocrinol. 20, 157 (1999); D. Hoyer, H. Lubbart, C. Bruns, Arch. Pharmacol. 350, 1 (1994).
4. Y. C. Patel, Frontiers Neuroendocrinol. 20, 157 (1999); D. Hoyer, H. Lubbart, C. Bruns, Arch. Pharmacol. 350, 1 (1994).
5. C. Missale, S, Russel Nash, S. W. Robinson, M. Jaber, M. G. Caron, Physiol. Rev. 78, 189 (1998); R. Picetti et al., Crit. Rev. Neurobiol. 11, 121 (1997).
6. C. Missale, S, Russel Nash, S. W. Robinson, M. Jaber, M. G. Caron, Physiol. Rev. 78, 189 (1998); R. Picetti et al., Crit. Rev. Neurobiol. 11, 121 (1997).
7. D. M. Weiner et al., Proc. Natl. Acad. Sci. U.S.A. 88, 1859 (1991).
8. J. Chneiweiss, J. Glowinski, J. Premont, J. Neurochem. 44, 1825 (1985).
9. M. T. Martin-Iverson, J. M. Radke, S. R. Vincent, Pharmacol. Biochem. Behav. 24, 17 (1986); E. K. Havlick et al., Pharmacol. Biochem. Behav. 4, 455 (1976); R. Leblanc et al., Neurology 38, 1887 (1988); A. J. Kastin, D. H. Coy, Y. Jacquet, A. V. Schally, N. P. Plotnikoff, Metabolism 27, 1247 (1978); M. L. Cohn and M. Cohn, Brain Res. 96, 138 (1975).
10. M. T. Martin-Iverson, J. M. Radke, S. R. Vincent, Pharmacol. Biochem. Behav. 24, 17 (1986); E. K. Havlick et al., Pharmacol. Biochem. Behav. 4, 455 (1976); R. Leblanc et al., Neurology 38, 1887 (1988); A. J. Kastin, D. H. Coy, Y. Jacquet, A. V. Schally, N. P. Plotnikoff, Metabolism 27, 1247 (1978); M. L. Cohn and M. Cohn, Brain Res. 96, 138 (1975).
11. M. T. Martin-Iverson, J. M. Radke, S. R. Vincent, Pharmacol. Biochem. Behav. 24, 17 (1986); E. K. Havlick et al., Pharmacol. Biochem. Behav. 4, 455 (1976); R. Leblanc et al., Neurology 38, 1887 (1988); A. J. Kastin, D. H. Coy, Y. Jacquet, A. V. Schally, N. P. Plotnikoff, Metabolism 27, 1247 (1978); M. L. Cohn and M. Cohn, Brain Res. 96, 138 (1975).
12. M. T. Martin-Iverson, J. M. Radke, S. R. Vincent, Pharmacol. Biochem. Behav. 24, 17 (1986); E. K. Havlick et al., Pharmacol. Biochem. Behav. 4, 455 (1976); R. Leblanc et al., Neurology 38, 1887 (1988); A. J. Kastin, D. H. Coy, Y. Jacquet, A. V. Schally, N. P. Plotnikoff, Metabolism 27, 1247 (1978); M. L. Cohn and M. Cohn, Brain Res. 96, 138 (1975).
13. M. T. Martin-Iverson, J. M. Radke, S. R. Vincent, Pharmacol. Biochem. Behav. 24, 17 (1986); E. K. Havlick et al., Pharmacol. Biochem. Behav. 4, 455 (1976); R. Leblanc et al., Neurology 38, 1887 (1988); A. J. Kastin, D. H. Coy, Y. Jacquet, A. V. Schally, N. P. Plotnikoff, Metabolism 27, 1247 (1978); M. L. Cohn and M. Cohn, Brain Res. 96, 138 (1975).
14. R. M. Izquierdo-Claros, M. C. Boyano-Adanez, C. Larsson, L. Gustavsson, E. Arilla, Brain Res. mol. Brain Res. 47, 99 (1997); M. N. Rodriguez-Sanchez et al., J. Neurosci. Res. 47, 238 (1997).
15. R. M. Izquierdo-Claros, M. C. Boyano-Adanez, C. Larsson, L. Gustavsson, E. Arilla, Brain Res. mol. Brain Res. 47, 99 (1997); M. N. Rodriguez-Sanchez et al., J. Neurosci. Res. 47, 238 (1997).
16. P. Marzullo et al., Pituitary 1, 115 (1999).
17. M. Rocheville et al., J. Biol. Chem. 275, 7862 (2000).
18. C. Y. K. Ng et al., Biochem. Biophys. Res. Commun. 227, 200 (1996); S. R. George et al., J. Biol. Chem. 273, 30244 (1998).
19. C. Y. K. Ng et al., Biochem. Biophys. Res. Commun. 227, 200 (1996); S. R. George et al., J. Biol. Chem. 273, 30244 (1998).
20. Adult male CD rats were anesthetized with ketamine and perfusion-fixed, and 40-μm coronal sections of brain were processed for double-label immunocytochemistry. Antipeptide antibodies to the cytoplasmic tail of hSSTR5 or residues 231 to 244 of the third intracellular loop of human D2R were produced in rabbits, validated by Western blots, and used as primary antibodies [U. Kumar et al., Diabetes 48, 77 (1999) ]. Sections were incubated with SSTR5 antibody (1:500) followed by incubation with fluorescein isothiocyanate (FITC)-conjugated antibody to rabbit immunoglobulin G (IgG) (1:100). The same sections were then exposed to D2R antibody (1:300), and receptor was visualized with Cy3-conjugated antibody to rabbit IgG (1:300). Because both primary antibodies were rabbit, the specificity of the immunofluorescent colocalization was validated by exposure of the SSTR5 labeled brain sections with the SSTR5 peptide immunogen for 3 to 4 hours at room temperature before incubation with D2R antibody. Coexpression of SSTR5 and D2R was also demonstrated independently in serial sections developed for SSTR5 and D2R localization by peroxidase immunocytochemistry
21. N. Hukovic, R. Panetta, U. Kumar, M. Rocheville, Y. C. Patel, J. Biol. Chem. 273, 21416 (1998).
22. Binding studies were carried out for 30 min at 37°C with 20 to 40 μg of membranes with subtype-specific radioligands (12). Receptor coupling to adenylyl cyclase was tested by incubating cells for 30 min with 1 μM forskolin with or without ligand at 37°C (12).
23. C. B. Srikant and Y. C Patel, Proc. Natl. Acad. Sci. U.S.A. 78, 3930 (1981).
24. D-A)
25. The photobleaching decay was analyzed for the plasma membrane region on a pixel-by-pixel basis as well as averaged over the entire image. Image analysis procedures and instrumental setup are described in (9). CHO-K1 cells stably cotransfected with HA-SSTR5 and D2R were grown on glass cover slips for 24 hours, treated with agonists or antagonists for 30 min at 37°C, fixed, and processed for immunocytochemistry. HA-SSTR5 and D2R were specifically labeled with FITC and rhodamine, respectively, using mouse monoclonal HA antibodies and rabbit polyclonal antibodies followed by reaction with conjugated secondary antibodies. Both reactions resulted in specific plasma membrane staining.
26. T. Förster, Naturwissenschaften 6, 166 (1948); T. M. Jovin and D. J. Arndt-Jovin, Cell Structure and Function by Microspectrofluorometry (Academic Press, New York, 1989); R. M. Clegg, in Fluorescence Imaging Spectroscopy and Microscopy, X. F. Wang and B. Herman, Eds. (Wiley-Interscience, New York, 1996).
27. T. Förster, Naturwissenschaften 6, 166 (1948); T. M. Jovin and D. J. Arndt-Jovin, Cell Structure and Function by Microspectrofluorometry (Academic Press, New York, 1989); R. M. Clegg, in Fluorescence Imaging Spectroscopy and Microscopy, X. F. Wang and B. Herman, Eds. (Wiley-Interscience, New York, 1996).
28. T. Förster, Naturwissenschaften 6, 166 (1948); T. M. Jovin and D. J. Arndt-Jovin, Cell Structure and Function by Microspectrofluorometry (Academic Press, New York, 1989); R. M. Clegg, in Fluorescence Imaging Spectroscopy and Microscopy, X. F. Wang and B. Herman, Eds. (Wiley-Interscience, New York, 1996).
29. B. A. Jordan and L. A. Devi, Nature 399, 697 (1999); F. H. Marshall, K. A. Jones, K. Kaupmann, B. Bettler, Trends Pharmacol. Sci. 20, 396 (1999); J. Wess and F. Y. Zeng, J. Biol. Chem. 274, 19487 (1999); T. E. Hebert and M. Bouvier, Biochem. Cell. Biol. 76, 1 (1998); S. Cvejic and L. A. Devi, J. Biol. Chem. 272, 26959 (1997).
30. B. A. Jordan and L. A. Devi, Nature 399, 697 (1999); F. H. Marshall, K. A. Jones, K. Kaupmann, B. Bettler, Trends Pharmacol. Sci. 20, 396 (1999); J. Wess and F. Y. Zeng, J. Biol. Chem. 274, 19487 (1999); T. E. Hebert and M. Bouvier, Biochem. Cell. Biol. 76, 1 (1998); S. Cvejic and L. A. Devi, J. Biol. Chem. 272, 26959 (1997).
31. B. A. Jordan and L. A. Devi, Nature 399, 697 (1999); F. H. Marshall, K. A. Jones, K. Kaupmann, B. Bettler, Trends Pharmacol. Sci. 20, 396 (1999); J. Wess and F. Y. Zeng, J. Biol. Chem. 274, 19487 (1999); T. E. Hebert and M. Bouvier, Biochem. Cell. Biol. 76, 1 (1998); S. Cvejic and L. A. Devi, J. Biol. Chem. 272, 26959 (1997).
32. B. A. Jordan and L. A. Devi, Nature 399, 697 (1999); F. H. Marshall, K. A. Jones, K. Kaupmann, B. Bettler, Trends Pharmacol. Sci. 20, 396 (1999); J. Wess and F. Y. Zeng, J. Biol. Chem. 274, 19487 (1999); T. E. Hebert and M. Bouvier, Biochem. Cell. Biol. 76, 1 (1998); S. Cvejic and L. A. Devi, J. Biol. Chem. 272, 26959 (1997).
33. B. A. Jordan and L. A. Devi, Nature 399, 697 (1999); F. H. Marshall, K. A. Jones, K. Kaupmann, B. Bettler, Trends Pharmacol. Sci. 20, 396 (1999); J. Wess and F. Y. Zeng, J. Biol. Chem. 274, 19487 (1999); T. E. Hebert and M. Bouvier, Biochem. Cell. Biol. 76, 1 (1998); S. Cvejic and L. A. Devi, J. Biol. Chem. 272, 26959 (1997).
34. T. W. Gadella and T. M. Jovin, J. Cell Biol. 129, 1543 (1995).
35. We thank H. H. Niznik for providing the cDNA for the long form of D2R, K. Koller for the cDNA for HA-SSTR5, and M. Correia for secretarial help. Supported by NIH grants NS32160-05 and NS34339 and Canadian Medical Research Council (MRC) grant MT-10411. Y.C.P. is a Distinguished Scientist of the MRC. M.R. is supported by a studentship from the Fonds de la Recherche en Santé du Quebec.